Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 5.01
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of EOLS is 14 and suggests 179% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only
Buy
Sell